MA27326A1 - Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 - Google Patents

Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Info

Publication number
MA27326A1
MA27326A1 MA28049A MA28049A MA27326A1 MA 27326 A1 MA27326 A1 MA 27326A1 MA 28049 A MA28049 A MA 28049A MA 28049 A MA28049 A MA 28049A MA 27326 A1 MA27326 A1 MA 27326A1
Authority
MA
Morocco
Prior art keywords
alpha
binding
mip
ccr1 receptor
piperidine derivatives
Prior art date
Application number
MA28049A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27326A1 publication Critical patent/MA27326A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATIONS DE PRIORITES US 18 juillet 2002 60/397,108 Dérivés de pipéridine et leur utilisation comme inhibiteurs sélectifs de la liaison de MIP-1 alpha à son récepteur CCR1 Un composé de formule (I) dans laquelle a, b, c, R1, R3,R4, R5, R6, R7, Q, W, Y et Z répondent aux définitions précitées, utile comme inhibiteur puissant et sélectif de la liaison de MlP-l(alpha) (CCL3) à son récepteur CCR1 présent sur des cellules inflammatoires et immunomodulatrices (de préférence les leucocytes et lymphocytes).
MA28049A 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 MA27326A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
MA27326A1 true MA27326A1 (fr) 2005-05-02

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28049A MA27326A1 (fr) 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Country Status (24)

Country Link
US (1) US20040063759A1 (fr)
EP (1) EP1534677A1 (fr)
JP (1) JP2005537279A (fr)
KR (1) KR20050021497A (fr)
CN (1) CN1668592A (fr)
AP (1) AP2005003200A0 (fr)
AR (1) AR040583A1 (fr)
AU (1) AU2003242941A1 (fr)
BR (1) BR0312946A (fr)
CA (1) CA2492651A1 (fr)
EC (1) ECSP055547A (fr)
HN (1) HN2003000222A (fr)
IL (1) IL166010A0 (fr)
IS (1) IS7614A (fr)
MA (1) MA27326A1 (fr)
MX (1) MXPA05000380A (fr)
OA (1) OA12885A (fr)
PA (1) PA8575901A1 (fr)
PE (1) PE20040666A1 (fr)
TN (1) TNSN05014A1 (fr)
TW (1) TW200402416A (fr)
UY (1) UY27897A1 (fr)
WO (1) WO2004009550A1 (fr)
ZA (1) ZA200500067B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
DE60328690D1 (de) 2002-06-12 2009-09-17 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
AP2005003196A0 (en) * 2002-07-18 2005-03-31 Pfizer Prod Inc Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (fr) 2004-03-03 2013-09-03 Chemocentryx, Inc. Heterocycles d'azote bicycliques et pontes
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
EP2441763A1 (fr) 2005-07-26 2012-04-18 Glaxo Group Limited Dérivés de benzylpipérazine utiles pour le traitement de troubles gastro-intestinaux
WO2007044885A2 (fr) 2005-10-11 2007-04-19 Chemocentryx, Inc. Derives de piperidine et leurs procedes d'utilisation
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2010077915A1 (fr) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Nouveaux composés utiles comme ligands de récepteur de chémokine cc
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
DK1179341T3 (da) * 1999-05-18 2006-03-27 Teijin Ltd Lægemidler eller forebyggende midler mod sygdomme der er associeret med chemokiner
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
PL216636B1 (pl) * 2001-07-24 2014-04-30 Richter Gedeon Vegyészeti Gyár RT Pochodne amidów kwasów karboksylowych, środek farmaceutyczny, sposób wytwarzania pochodnych amidów kwasów karboksylowych, sposób wytwarzania środka farmaceutycznego i zastosowanie pochodnych amidów kwasów karboksylowych

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions

Also Published As

Publication number Publication date
JP2005537279A (ja) 2005-12-08
US20040063759A1 (en) 2004-04-01
UY27897A1 (es) 2004-02-27
PE20040666A1 (es) 2004-09-25
KR20050021497A (ko) 2005-03-07
IS7614A (is) 2004-12-23
HN2003000222A (es) 2004-11-23
AP2005003200A0 (en) 2005-03-31
MXPA05000380A (es) 2005-03-31
CA2492651A1 (fr) 2004-01-29
ECSP055547A (es) 2005-03-10
EP1534677A1 (fr) 2005-06-01
OA12885A (en) 2006-09-15
BR0312946A (pt) 2005-07-12
CN1668592A (zh) 2005-09-14
TNSN05014A1 (fr) 2007-05-14
AR040583A1 (es) 2005-04-13
PA8575901A1 (es) 2004-07-20
WO2004009550A1 (fr) 2004-01-29
AU2003242941A1 (en) 2004-02-09
IL166010A0 (en) 2006-01-15
TW200402416A (en) 2004-02-16
ZA200500067B (en) 2005-11-02

Similar Documents

Publication Publication Date Title
MA27326A1 (fr) Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1
MA27327A1 (fr) Derives de piperidine bicycliques servant d'antagonistes du recepteur de chimiokine ccr1
HK1252078A1 (zh) 影響減重的組合物
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
RU2008127257A (ru) Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
NO20012194D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
MEP19008A (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
WO2003066621A8 (fr) Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
DE69817810D1 (de) Cyanoguanidine als zellproliferation inhibitoren
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
CO5210926A1 (es) Mezclas fungicidas
DE60117517D1 (de) Indolderivate als mcp-1 rezeptor antagonisten
NO20030509L (no) Nye N-(2-fenyl-3-aminopropyl)naftamider
CO5160316A1 (es) N-oxidos de las correspondientes bases libres inhibidoras de la fosfodiesterasa iv y su uso para el tratamiento de enfer- medades inflamatorias